SCHEMBL4945452

SCHEMBL4945452

COc1ccc(CNC(=O)CCc2nnc(SCc3cccc(C)c3)n2-c2cccc(OC)c2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.56
NPSR1 Q6W5P4 5/20 0.56
MAPT P10636 2/20 0.50
HTT P42858 3/20 0.49
ALOX12 P18054 1/20 0.49
USP2 O75604 1/20 0.49
HPGD P15428 1/20 0.49
HSD17B10 Q99714 1/20 0.49
LMNA P02545 5/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
MAPK1 P28482 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C19 P33261 2/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
TP53 P04637 2/20 0.46
TSHR P16473 1/20 0.46
MEN1 O00255 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4941521 0.94 ALDH1A1 (0.54) ALDH1A1NPSR1MAPTHTTALOX12
SCHEMBL4945036 0.91 ALDH1A1 (0.56) ALDH1A1NPSR1MAPTHTTUSP2
SCHEMBL4940554 0.89 ALDH1A1 (0.47) ALDH1A1NPSR1MAPTHTTALOX12
SCHEMBL4945572 0.89 ALDH1A1 (0.53) ALDH1A1NPSR1MAPTUSP2HPGD
SCHEMBL4943908 0.88 USP2 (0.47) ALDH1A1NPSR1MAPTHTTALOX12
SCHEMBL4938033 0.88 ALDH1A1 (0.54) ALDH1A1NPSR1MAPTHTTALOX12
SCHEMBL4941949 0.88 HPGD (0.46) ALDH1A1NPSR1MAPTHTTALOX12
SCHEMBL4944918 0.86 ALDH1A1 (0.56) ALDH1A1NPSR1MAPTHTTHPGD
SCHEMBL4943341 0.85 ALDH1A1 (0.56) ALDH1A1NPSR1MAPTHTTLMNA
SCHEMBL6616046 0.85 NPSR1 (0.58) ALDH1A1NPSR1MAPTHTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US claimed
EP-1458381-B1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS (AN) 2005-11-30 EP claimed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US claimed
EP-1458381-A1 TRIAZOLES AS OXYTOCIN ANTAGONISTS Applied Research Systems ARS Holding N.V. (AN) 2004-09-22 EP claimed
WO-2003053437-A1 TRIAZOLES AS OXYTOCIN ANTAGONISTS APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2003-07-03 WO claimed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-7468385-B2 Triazoles as oxytocin antagonists LABORATOIRES SERONO SA (CH) 2008-12-23 US disclosed
US-20050187275-A1 Triazoles as oxytocin antagonists APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) 2005-08-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050187275-A1 Triazoles as oxytocin antagonists OXTR, AVPR2, AVPR1B ALDH1A1 4091/4885NPSR1 17/4885MAPT 3974/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.